Investing in human longevity

We are a seed and Series A VC with $37M under management, investing in companies that will allow us to live longer and healthier lives. 

Learn more about the science
 or jump to the portfolio
Image

Portfolio



background

Get rid of old cells

Unity's first focus is elimninating senescent cells. Completed an $85M IPO in 2018.
background

Experts in mTOR biology

Modulate mTOR activity to treat disease. Entered human clinical studies June 2018.
background

Novel drugs for liver disease

Salk Institute spinout. After a $65M Series C, initiated dosing of first patient in June 2018.
background

Engineer macrophages

Stanford spinout with a $36M Series A for CD47 biology. Phase 1 trial results in June 2018.
background

High-precision genome editing

ARCUS platform for genetic engineering. $110M Series B in June 2018.
background

Advancing hearing loss biology

Platform for inner ear biology. Closed $55M Series C in June 2018.

Portfolio News

Contact

background

E: info@longevity.vc

Longevity entrepreneur? Send us a line!